(NASDAQ: XNCR) Xencor's forecast annual revenue growth rate of -12.48% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Xencor's revenue in 2024 is $168,338,000.On average, 4 Wall Street analysts forecast XNCR's revenue for 2024 to be $5,722,385,466, with the lowest XNCR revenue forecast at $1,191,845,304, and the highest XNCR revenue forecast at $11,857,332,768. On average, 4 Wall Street analysts forecast XNCR's revenue for 2025 to be $6,916,186,619, with the lowest XNCR revenue forecast at $4,033,937,952, and the highest XNCR revenue forecast at $12,060,863,274.
In 2026, XNCR is forecast to generate $6,413,350,141 in revenue, with the lowest revenue forecast at $127,741,368 and the highest revenue forecast at $12,698,958,913.